Sintx Technologies stock analysis
Sintx Technologies (0A8S) Share Price & Analysis
0A8S Stock Chart & Stats
- Day’s Range
- $1.38 - $1.54
- 52-Week Range
- $1.38 - $4.40
- Previous Close
- $1.58
- Volume
- N/A
- Average Volume (3M)
- 162
- Market Cap
- $11.64M
- Enterprise Value
- $15.86M
- Total Cash (Recent Filing)
- $2.00M
- Total Debt (Recent Filing)
- $3.00M
- Price to Earnings (P/E)
- ―
- Beta
- 1.62
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin Expansion
The sharp revenue increase alongside materially higher gross margin indicates improving commercial traction and product economics. If sustained beyond the recent quarter, this combination can increase operating leverage, support reinvestment in commercialization, and strengthen the company’s ability to scale its materials platform.
Commercialization Of FDA-Cleared Product
Regulatory clearance followed by limited-use release and initial revenue represents progress from development toward commercial adoption. Broader clinical use could create a repeatable product channel, validate silicon nitride in orthopedics, and support expansion of the company’s medical technology portfolio.
Order Backlog And Industrial Traction
Shipment activity against sizable customer orders provides tangible evidence that the company can convert its materials capabilities into commercial revenue. Continued execution could improve revenue visibility, deepen customer relationships, and establish a foundation for more diversified sales across industrial and medical applications.
Bears Say
Persistent Losses And Cash Burn
Large operating and net losses, combined with deeply negative free cash flow, show that the current revenue base does not yet support the cost structure. Continued cash consumption can constrain investment, increase dependence on external funding, and delay the point at which growth translates into durable financial self-sufficiency.
Going-Concern And Liquidity Risk
A low cash balance relative to ongoing losses and explicit going-concern language indicate limited financial flexibility. The company may need additional equity or debt financing to maintain operations, creating funding uncertainty and potentially diverting management attention from product development and commercial execution.
Uncertain Order Conversion And Margin Durability
Announced orders do not automatically become recognized revenue because several technical and customer milestones remain necessary. Delays or quality issues could shift revenue timing, while product mix and manufacturing efficiency may reduce margins, making near-term growth less predictable and harder to forecast.
Sintx Technologies News
0A8S FAQ
What was Sintx Technologies’s price range in the past 12 months?
What is Sintx Technologies’s market cap?
When is Sintx Technologies’s upcoming earnings report date?
How were Sintx Technologies’s earnings last quarter?
Is Sintx Technologies overvalued?
Does Sintx Technologies pay dividends?
What is Sintx Technologies’s EPS estimate?
How many shares outstanding does Sintx Technologies have?
What happened to Sintx Technologies’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sintx Technologies?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Sintx Technologies
Sintx Technologies, Inc. is an advanced materials enterprise dedicated to researching, developing, and commercializing medical devices crafted from silicon nitride. These innovative products serve biomedical, industrial, and antipathogenic uses, primarily marketed across the United States. Its diverse portfolio includes solid and porous silicon nitride, silicon nitride powder, and specialized coating products, along with advanced silicon nitride composite materials and polyetherketoneketone. Established in 1996, this company, once known as Amedica Corporation, has its corporate headquarters situated in Salt Lake City, Utah.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Eric K. Olson
- Employees
- 32
- Website
- www.sintx.com
- Address
- 1885 West 2100 South, Salt Lake City, UT, 84119, US
Sintx Technologies (0A8S) Earnings & Revenues
0A8S Earnings Call
Earnings Call SentimentNeutral
The call conveyed meaningful commercial progress: strong year-over-year revenue and product revenue growth, higher gross profit and margins, significant purchase orders (> $3.2M), FDA clearance and first clinical use of the SiNAPTIC wedge, and access to additional financing. However, progress is tempered by persistent net losses, elevated operating cash burn, a low cash balance (~$3.6M), substantial doubt about going concern, increased working capital and G&A expenses, and uncertainty about the timing and conversion of announced orders into recognized revenue. The narrative is constructive on execution and go-to-market priorities but balanced by clear liquidity and execution risks.
View all GB:0A8S earnings summaries0A8S Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |










